Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

Haematologica
José Luis PiñanaGELTAMO Group

Abstract

Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen within prospective trials. The prospective multicenter studies considered included 37 patients with follicular lymphoma who underwent allogeneic stem cell transplantation between 1998 and 2007 with a fludarabine plus melphalan-based reduced intensity conditioning regimen. The median age of the patients was 50 years (range, 34-62 years) and the median follow-up was 52 months (range, 0.6 to 113 months). Most patients (77%) had stage III-IV at diagnosis, and patients had received a median of three lines of therapy before the reduced intensity conditioning allogeneic stem cell...Continue Reading

References

Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo CorradiniCorrado Tarella
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Dec 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew R RezvaniDavid G Maloney
Jan 25, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Parameswaran HariKoen van Besien
Jan 29, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohammed Sorror

❮ Previous
Next ❯

Citations

Oct 10, 2013·Current Opinion in Hematology·Andrew R Rezvani, Brenda M Sandmaier
Jun 20, 2014·Journal of Clinical and Experimental Hematopathology : JCEH·Sung Won Kim
Oct 6, 2010·Leukemia & Lymphoma·Vladimir L J LazarevicJan-Erik Johansson
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ryan D CassadayAjay K Gopal
Mar 14, 2012·Best Practice & Research. Clinical Haematology·N SchmitzB Glaß
Jan 25, 2012·Experimental Hematology·Wichai ChinratanalabBipin N Savani
Jun 11, 2011·Best Practice & Research. Clinical Haematology·Issa F Khouri
Aug 9, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Evgeny KlyuchnikovMehdi Hamadani
May 19, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pere BarbaJorge Sierra
Apr 26, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ginna G Laport
Dec 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sandra CohenJean Roy
Jan 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Laurie H SehnGinna G Laport
Nov 16, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marcie R TomblynGinna G Laport
Dec 10, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Craig S SauterHugo Castro-Malaspina
Apr 28, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ginna G LaportUNKNOWN Blood and Marrow Transplant Clinical Trials Network
May 2, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Timothy S FenskeChristopher Bredeson
Aug 20, 2016·Expert Review of Hematology·Saveria CapriaAlessandro Pulsoni
Apr 4, 2017·Bone Marrow Transplantation·M A Kharfan-DabajaM Hamadani
Dec 13, 2017·Journal of Oncology Practice·Mehdi Hamadani, Mary M Horowitz
Jan 1, 2012·American Society of Clinical Oncology Educational Book·Theodore S HongEunice L Kwak
Jun 20, 2012·Cancer Control : Journal of the Moffitt Cancer Center·Ernesto Ayala

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.